Wednesday 28 February 2024
Salisbury Foundation Trust

FOI_7303

Internal Reference Number: FOI_7303

Date Request Received: 12/07/2023 00:00:00

Date Request Replied To: 03/08/2023 00:00:00

This response was sent via: By Email

Request Summary: Lung cancer

Request Category: Private Individuals

 
Question Number 1:
In the past 3 months, how many early-stage (non-metastatic or Stages 1-3) Non-small cell lung cancer patients received the following treatments:

Atezolizumab

Durvalumab

Nivolumab

Pembrolizumab

Chemotherapy (Platinum, Taxane, Vinorelbine, Gemcitabine, Pemetrexed) only

Radiotherapy only

Chemotherapy + radiotherapy
 
Answer To Question 1:
Atezolizumab <5

Durvalumab <5

Nivolumab <5

Pembrolizumab 0

Chemotherapy (Platinum, Taxane, Vinorelbine, Gemcitabine, Pemetrexed) only 0

Radiotherapy only - we do not do radiotherapy at this Trust so unable to respond to this and the category below

Chemotherapy + radiotherapy
 
To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.

Person Centred & Safe

Professional

Responsive

Friendly

Progressive

Salisbury NHS Foundation Trust, Salisbury District Hospital, Odstock Road, Salisbury, Wiltshire, SP2 8BJ
T: 01722 336262 E: sft.pals@nhs.net
© 2024 Salisbury NHS Foundation Trust
Trust Values